Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 4
1981 3
1982 3
1983 7
1984 6
1985 5
1986 7
1987 1
1988 2
1991 1
1994 1
1995 3
1996 2
1997 2
1998 1
1999 1
2000 1
2001 5
2002 4
2004 2
2005 3
2006 5
2007 1
2008 10
2009 11
2010 18
2011 10
2012 11
2013 4
2014 10
2015 12
2016 12
2017 7
2018 2
2019 6
2020 3
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

176 results
Results by year
Filters applied: . Clear all
Page 1
Fenofibric acid for hyperlipidemia.
Saurav A, Kaushik M, Mohiuddin SM. Saurav A, et al. Expert Opin Pharmacother. 2012 Apr;13(5):717-22. doi: 10.1517/14656566.2012.658774. Epub 2012 Mar 9. Expert Opin Pharmacother. 2012. PMID: 22404421 Review.
AREAS COVERED: This article reviews the role of fenofibric acid in the context of results from recent randomized trials on fenofibrate, including the ACCORD Trial. It discusses the current status of fenofibric acid in the management of dyslipidemia, es …
AREAS COVERED: This article reviews the role of fenofibric acid in the context of results from recent randomized trials on fen …
Fenofibric Acid Can Cause False-Positive Urine Methylenedioxymethamphetamine Immunoassay Results.
Quesada L, Gomila I, Fe A, Servera MA, Yates C, Morell-Garcia D, Castanyer B, Barceló B. Quesada L, et al. J Anal Toxicol. 2015 Nov-Dec;39(9):734-40. doi: 10.1093/jat/bkv074. Epub 2015 Jul 22. J Anal Toxicol. 2015. PMID: 26203185
We present a false-positive result of ecstasy (3,4-methylenedioxy-NN-methylamphetamine) screening due to the therapeutic use of fenofibrate, an antihyperlipidemic drug. Our hypothesis was that the main metabolite of fenofibrate, fenofibric acid, was re …
We present a false-positive result of ecstasy (3,4-methylenedioxy-NN-methylamphetamine) screening due to the therapeutic use o …
Comparison table: Some lipid-lowering drugs.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 Feb 11;61(1565):e24-e30. Med Lett Drugs Ther. 2019. PMID: 30845107 No abstract available.
Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.
Yang LP, Keating GM. Yang LP, et al. Am J Cardiovasc Drugs. 2009;9(6):401-9. doi: 10.2165/11203920-000000000-00000. Am J Cardiovasc Drugs. 2009. PMID: 19929038
Fenofibric acid activates peroxisome proliferator-activated receptor alpha to modify fatty acid and lipid metabolism. Fenofibric acid is the first member of the fibric acid derivatives (fibrates) class approved for use as combinati
Fenofibric acid activates peroxisome proliferator-activated receptor alpha to modify fatty acid and lipid metabolism.
Fenofibric Acid (trilipix).
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2009 May 4;51(1311):33-4. Med Lett Drugs Ther. 2009. PMID: 19417718 No abstract available.
Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration.
Qiu F, Meng T, Chen Q, Zhou K, Shao Y, Matlock G, Ma X, Wu W, Du Y, Wang X, Deng G, Ma JX, Xu Q. Qiu F, et al. Mol Pharm. 2019 May 6;16(5):1958-1970. doi: 10.1021/acs.molpharmaceut.8b01319. Epub 2019 Mar 26. Mol Pharm. 2019. PMID: 30912953 Free PMC article.
The present study aimed to explore the sustained therapeutic effects of fenofibrate-loaded biodegradable nanoparticles (NP) on both DR and neovascular age-related macular degeneration (AMD). ...Feno-NP (PLGA 34 kDa) was selected for following in vivo studies, and one singl …
The present study aimed to explore the sustained therapeutic effects of fenofibrate-loaded biodegradable nanoparticles (NP) on both D …
Absolute oral bioavailability of fenofibric acid and choline fenofibrate in rats determined by ultra-performance liquid chromatography tandem mass spectrometry.
Wei X, Li P, Liu M, Du Y, Wang M, Zhang J, Wang J, Liu H, Liu X. Wei X, et al. Biomed Chromatogr. 2017 Apr;31(4). doi: 10.1002/bmc.3832. Epub 2016 Oct 10. Biomed Chromatogr. 2017. PMID: 27594083
Choline fenofibrate is the choline salt of fenofibric acid, which releases free fenofibric acid in the gastrointestinal tract. ...This method successfully supported the determination of fenofibric acid and choline fenofibrate. The absolut …
Choline fenofibrate is the choline salt of fenofibric acid, which releases free fenofibric acid in the gastroint …
Effects of fenofibric acid on diabetic macular edema: the MacuFen study.
Massin P, Peto T, Ansquer JC, Aubonnet P, MacuFEN Study Investigators FT. Massin P, et al. Ophthalmic Epidemiol. 2014 Oct;21(5):307-17. doi: 10.3109/09286586.2014.949783. Epub 2014 Aug 18. Ophthalmic Epidemiol. 2014. PMID: 25133794 Clinical Trial.
PURPOSE: Fenofibrate reduced progression of diabetic retinopathy in two large randomized studies. The effect of 135 mg fenofibric acid on diabetic macular edema (DME) was evaluated in subjects with existing DME. ...Triglycerides decreased by 23% after fenofibric
PURPOSE: Fenofibrate reduced progression of diabetic retinopathy in two large randomized studies. The effect of 135 mg fenofibric
Novel fenofibric acid-loaded controlled release pellet bioequivalent to choline fenofibrate-loaded commercial product in beagle dogs.
Kim KS, Jin SG, Mustapha O, Yousaf AM, Kim DW, Kim YH, Kim JO, Yong CS, Woo JS, Choi HG. Kim KS, et al. Int J Pharm. 2015 Jul 25;490(1-2):273-80. doi: 10.1016/j.ijpharm.2015.05.059. Epub 2015 May 27. Int J Pharm. 2015. PMID: 26024820
The objective of this study was to develop a novel fenofibric acid-loaded controlled release pellet showing enhanced, or equivalent to, bioavailability compared with two commercially available products containing fenofibrate or choline fenofibrate. ...Thus, this pel …
The objective of this study was to develop a novel fenofibric acid-loaded controlled release pellet showing enhanced, or equiv …
Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans.
Zhu T, Ansquer JC, Kelly MT, Sleep DJ, Pradhan RS. Zhu T, et al. J Clin Pharmacol. 2010 Aug;50(8):914-21. doi: 10.1177/0091270009354995. Epub 2010 Feb 9. J Clin Pharmacol. 2010. PMID: 20145261 Clinical Trial.
This study compared the gastrointestinal (GI) absorption characteristics and absolute bioavailability of fenofibric acid and fenofibrate (which is converted to fenofibric acid in vivo) in healthy volunteers. ...Serial blood samples were collected for 1 …
This study compared the gastrointestinal (GI) absorption characteristics and absolute bioavailability of fenofibric acid and f …
176 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page